Pacific Biosciences Further Expands Leadership Team with Appointment of Dr. Catherine Ball to Newly Created Position of Seni...
May 17 2021 - 4:05PM
Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading
provider of high-quality, long-read sequencing platforms, today
announced the appointment of three new hires to its growing team.
Dr. Catherine Ball joins the company as Senior Vice President of
Research, Kathleen Lynch joins as Head of Global Government Affairs
and Corporate Communications, and Michele Farmer joins as Chief
Accounting Officer.
Dr. Ball is a product of the California education system having
completed her PhD in Molecular Biology at UCLA and her Postdoctoral
research at Berkeley prior to 17 years at Stanford. Most recently,
she was the Chief Scientific Officer of AncestryDNA where over the
course of nine years she built and led a team of population
geneticists, statisticians, computer scientists and laboratory
scientists to create the scientific roadmap, genotyping platform,
and analytical approaches behind the AncestryDNA and AncestryHealth
direct-to-consumer products and services.
“Cathy is a proven, high-impact executive and scientist with the
personal mission to bring the benefits of genomics to people
around the world,” shared Mark Van Oene, Chief Operations
Officer at PacBio. “In building and leading this new function,
Cathy will focus on expanding the team and directing investments
into early research and technology development activities to
broaden our toolkit and feed our product development pipeline so we
can positively impact health care innovation.”
“It is an exciting time to join PacBio and I am honored to have
the opportunity to join the talented teams as we make research and
collaboration investments to further explore PacBio’s current
products, open new long-read markets with complete applications and
investigate additional technologies and approaches to build a
multi-omic portfolio,” said Dr. Catherine Ball, Senior Vice
President of Research at PacBio.
Kathy Lynch brings a deep and diverse background in healthcare
and biotech, to this newly created role to lead global government
affairs and corporate communications. Kathy joins PacBio from
Illumina where she started the company’s government affairs efforts
in 2015 and served as the Vice President of Global Government
Affairs and Public Policy. Kathy previously guided government
affairs and held leadership roles at Thermo Fisher Scientific, Life
Technologies and Invitrogen. Kathy received her Bachelor of Arts
from the University of New Hampshire and her Juris Doctorate from
St. John’s University School of Law.
“Over her career within the genomics ecosystem, Kathy has
established herself as a key driver who creates and implements
strategies to propel access to genomics technology globally,” said
Christian Henry, President and CEO of PacBio. “Our team is
excited to have Kathy on board as we believe her unique expertise
at the intersection of innovation, business and policy will be a
force-multiplier as we more deeply embed ourselves in the genomics
community to advance human health.”
“I have dedicated my career to work across constituencies to
drive the adoption of innovative technologies in healthcare and
biotech and I am thrilled to join the impressive team at PacBio,”
said Kathy Lynch, Head of Global Government Affairs and Corporate
Communications at PacBio.
Michele Farmer joins PacBio from Illumina, where she was the
Senior Director of Accounting. She joined Illumina in 2009
and has more than sixteen years of progressive experience in
accounting, finance, and auditing roles. Michele most recently led
a team responsible for general accounting, consolidation,
revenue recognition, mergers and acquisitions, financial systems,
financial reporting, and technical accounting. Michele is
passionate about building and growing teams to support the
company’s strategic goals and objectives. Prior to joining
Illumina, Michele started her career as an auditor with
PricewaterhouseCoopers. Michele is a Certified Public
Accountant and earned her bachelor’s degree in Accounting from
San Diego State University.
“We are thrilled to welcome Michele and her deep finance
experience to our team as we drive our business forward in this new
phase of commercialization and growth,” said Susan Kim, Chief
Financial Officer at PacBio. “Michele’s leadership, extensive
knowledge of the field and passion for genomics and its potential
to meaningfully improve human health are a perfect addition to our
team.”
“I am grateful to join the PacBio team at this pivotal time as
we dramatically increase our infrastructure and operations to
support sustained long-term growth,” shared Michele Farmer, Chief
Accounting Officer at PacBio. “The opportunity to continue my
career with this team and lead this function is truly
exciting.”
About Pacific BiosciencesPacific Biosciences of
California, Inc. (NASDAQ: PACB) is empowering life scientists with
highly accurate long-read sequencing. The company’s innovative
instruments are based on Single Molecule, Real-Time (SMRT®)
Sequencing technology, which delivers a comprehensive view of
genomes, transcriptomes, and epigenomes, enabling access to the
full spectrum of genetic variation in any organism. Cited in
thousands of peer-reviewed publications, PacBio® sequencing systems
are in use by scientists around the world to drive discovery in
human biomedical research, plant and animal sciences, and
microbiology. For more information, please
visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only.
Not for use in diagnostic procedures.
Forward-Looking Statements This press release
may contain “forward-looking statements” within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, and
the U.S. Private Securities Litigation Reform Act of 1995,
including statements relating to anticipated growth and
commercialization efforts, and strategic priorities and direction.
Readers are cautioned not to place undue reliance on these
forward-looking statements and any such forward-looking statements
are qualified in their entirety by reference to the following
cautionary statements. All forward-looking statements speak only as
of the date of this report and are based on current expectations
and involve a number of assumptions, risks and uncertainties that
could cause the actual results to differ materially from such
forward-looking statements. Readers are strongly encouraged to read
the full cautionary statements contained in the Company’s filings
with the Securities and Exchange Commission, including the risks
set forth in the company’s Forms 8-K, 10-K, and 10-Q. The Company
disclaims any obligation to update or revise any forward-looking
statements.
Contacts
Investors:Todd
Friedman650.521.8450ir@pacificbiosciences.com
Media:Jen
Carroll858.449.8082pr@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Sep 2023 to Sep 2024